Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design DOI
Yu Chen, Fengyuan Liu,

Samira Pal

et al.

Chemical Society Reviews, Journal Year: 2024, Volume and Issue: 53(19), P. 9582 - 9608

Published: Jan. 1, 2024

Targeted protein degradation (TPD) has emerged as a revolutionary paradigm in drug discovery and development, offering promising avenue to tackle challenging therapeutic targets. Unlike traditional approaches that focus on inhibiting function, TPD aims eliminate proteins of interest (POIs) using modular chimeric structures. This is achieved through the utilization proteolysis-targeting chimeras (PROTACs), which redirect POIs E3 ubiquitin ligases, rendering them for by cellular ubiquitin-proteasome system (UPS). Additionally, other technologies such lysosome-targeting (LYTACs) autophagy-based degraders facilitate transportation endo-lysosomal or autophagy-lysosomal pathways degradation, respectively. Despite significant growth preclinical research, many fail progress beyond this stage development. Various factors contribute limited success agents, including hurdle inadequate delivery target site. Integrating into platforms could surmount challenges

Language: Английский

Tailoring drug delivery systems by microfluidics for tumor therapy DOI
Qingfei Zhang, Gaizhen Kuang, Li Wang

et al.

Materials Today, Journal Year: 2024, Volume and Issue: 73, P. 151 - 178

Published: Jan. 30, 2024

Language: Английский

Citations

14
Salivary Amylase‐Responsive Buccal Tablets Wipe Out Chemotherapy‐Rooted Refractory Oral Mucositis DOI Creative Commons
Yan Zhang,

Taixia Wang,

Xiulin Dong

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(11)

Published: Jan. 16, 2024

Abstract Oral mucositis (OM) is the most common and refractory complication of cancer chemotherapy radiotherapy, severely affecting patients’ life quality, lowering treatment tolerance, discouraging patient compliance. Current OM delivery systems mostly affect comfort use lead to poor compliance unsatisfactory effects. Herein, salivary amylases (SAs)‐responsive buccal tablets consisting porous manganese‐substituted Prussian blue (PMPB) nanocubes (NCs), anti‐inflammatory apremilast (Apr) starch controller have been engineered. PMPB NCs with large surface area can serve as carriers load Apr, their multienzyme‐mimicking activity enables them scavenge reactive oxygen species (ROS), which thus synergize Apr mitigate inflammation. More significantly, respond abundant SAs in oral cavity realize cascade, continuous, complete drug release after enzymatic decomposition, not only aids high tissue affinity prolong resistance time but also improves use. The preclinical study reveals that contributed by above actions, such inflammation, promote endothelium proliferation migration, accelerate wound healing for repressing chemotherapy‐originated intractable positive microenvironment shorter recovery time, holding potentials clinical translation.

Language: Английский

Citations

12
Oral administration microrobots for drug delivery DOI Creative Commons

An Ren,

Jiarui Hu, Changwei Qin

et al.

Bioactive Materials, Journal Year: 2024, Volume and Issue: 39, P. 163 - 190

Published: May 21, 2024

Oral administration is the most simple, noninvasive, convenient treatment. With increasing demands on targeted drug delivery, traditional oral treatment now facing some challenges: 1) biologics how to implement and ensure bioavailability not lower than subcutaneous injections; 2) How achieve therapy of drugs in gastrointestinal tract? Based these two issues, delivery microrobots have shown great application prospect due their characteristics flexible locomotion or driven ability. Therefore, this paper summarizes various developed recent years divides them into four categories according different driving modes: magnetic-controlled microrobots, anchored self-propelled biohybrid microrobots. As involve disciplines such as materials science, mechanical engineering, medicine, control systems, begins by introducing barriers that must overcome. Subsequently, it provides an overview typical involved design process To enhance readers' understanding working principles we present a guideline for designing Furthermore, current development status types reviewed, summarizing respective advantages limitations. Finally, considering significant concerns regarding safety clinical translation, discuss challenges prospections translation presented paper, providing corresponding suggestions addressing existing challenges.

Language: Английский

Citations

12
Ursodeoxycholic Acid‐Decorated Zwitterionic Nanoparticles for Orally Liver‐Targeted Close‐Looped Insulin Delivery DOI
Yuhong Ma, Wei Wang,

Caihua Li

et al.

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(7)

Published: Jan. 21, 2024

Abstract Oral insulin therapies targeting the liver and further simulating close‐looped secretion face significant challenges due to multiple trans‐epithelial barriers. Herein, ursodeoxycholic acid (UDCA)‐decorated zwitterionic nanoparticles (NPs) (UC‐CMs@ins) are designed overcome these barriers, target liver, respond glycemia, thereby achieving oral one‐time‐per‐day therapy. UC‐CMs@ins show excellent mucus permeability through introduction of zwitterion (carboxy betaine, CB). Furthermore, possess superior cellular internalization via proton‐assisted amino transporter 1 (PAT1, CB‐receptor) apical sodium‐dependent bile (ASBT, UDCA‐receptor) pathways. Moreover, exhibit endolysosomal escape ability improve basolateral release into bloodstream ileal acid‐binding protein heteromeric organic solute (OSTα‐ OSTβ) routes compared with non‐UDCA‐decorated C‐CMs@ins. Therefore, CB UDCA jointly intestinal Additionally, prevent degradation in gastrointestinal tract for crosslinked structure, accumulation introduction, effectively regulate glycemia “closed‐loop” glucose control. Surprisingly, ingestion shows a effect on (≈22 h, normoglycemia) improves postprandial glycemic levels diabetic mice, illustrating enormous potential prepared NPs as platform administration diabetes treatment.

Language: Английский

Citations

10
Orally available dextran-aspirin nanomedicine modulates gut inflammation and microbiota homeostasis for primary colorectal cancer therapy DOI
Sheng Ma, Haochen Yao,

Xinghui Si

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 370, P. 528 - 542

Published: May 10, 2024

Language: Английский

Citations

10
Mechanistic insights into the nutritional and therapeutic potential of Spirulina (Arthrospira) spp.: Challenges and opportunities DOI
Muhammad Abdur Rehman Shah, Feifei Zhu, Yi Cui

et al.

Trends in Food Science & Technology, Journal Year: 2024, Volume and Issue: 151, P. 104648 - 104648

Published: July 24, 2024

Language: Английский

Citations

10
Harnessing nanotechnology for cancer treatment DOI Creative Commons
Jiajun Zhu,

H. H. Lee,

Rong Huang

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 20, 2025

Nanotechnology has become a groundbreaking innovation force in cancer therapy, offering innovative solutions to the limitations of conventional treatments such as chemotherapy and radiation. By manipulating materials at nanoscale, researchers have developed nanocarriers capable targeted drug delivery, improving therapeutic efficacy while reducing systemic toxicity. Nanoparticles like liposomes, dendrimers, polymeric nanomaterials shown significant promise delivering chemotherapeutic agents directly tumor sites, enhancing bioavailability minimizing damage healthy tissues. In addition with utilization tools quantum dots nanosensors that enables more precise identification biomarkers, nanotechnology is also playing pivotal role early detection diagnosis. Furthermore, nanotechnology-based strategies, including photothermal gene therapy immunotherapy are novel ways combat by selectively targeting cells immune response. Nevertheless, despite these progressions, obstacles still persist, particularly clinical translation technologies. Issues nanoparticle toxicity, biocompatibility, complexity regulatory approval hinder widespread adoption nanomedicine oncology. This review discusses different applications highlighting its potential hurdles implementation. Future research needs concentrate on addressing unlock full providing personalized, effective, minimally invasive treatments.

Language: Английский

Citations

1
Targeted protein delivery based on stimuli‐triggered nanomedicine DOI Creative Commons
Jinzhao Liu, Yang Zhou,

Qingyang Lyu

et al.

Exploration, Journal Year: 2023, Volume and Issue: 4(3)

Published: Nov. 23, 2023

Abstract Protein‐based drugs have shown unique advantages to treat various diseases in recent years. However, most protein therapeutics clinical use are limited extracellular targets with low delivery efficiency. To realize targeted delivery, a series of stimuli‐triggered nanoparticle formulations been developed improve efficiency and reduce off‐target release. These smart nanoparticles designed release cargo proteins response either internal or external stimuli at pathological tissues. In this way, varieties protein‐based including antibodies, enzymes, pro‐apoptotic can be effectively delivered desired sites for the treatment cancer, inflammation, metabolic diseases, so on minimal side effects. review, advances design nanomedicine different biomedical applications will discussed. A deeper understanding these emerging strategies helps develop more efficient systems future.

Language: Английский

Citations

19
Anti‐inflammatory Glycocalyx‐Mimicking Nanoparticles for Colitis Treatment: Construction and In Vivo Evaluation DOI Creative Commons
Dohyun Yoo, Chang‐Hee Whang, Jungwoo Hong

et al.

Angewandte Chemie International Edition, Journal Year: 2023, Volume and Issue: 62(34)

Published: June 13, 2023

Common medications for treating inflammatory bowel disease (IBD) have limited therapeutic efficacy and severe adverse effects. This underscores the urgent need novel approaches that can effectively target inflamed sites in gastrointestinal tract upon oral administration, exerting potent while minimizing systemic Here, we report construction vivo evaluation of a library anti-inflammatory glycocalyx-mimicking nanoparticles (designated GlyNPs) mouse model IBD. The GlyNP was created by attaching bilirubin (BR) to glycopolymers composed random combinations five most naturally abundant sugars. Direct screening 31 BR-attached GlyNPs via administration into mice with acute colitis led identification candidate capable targeting macrophages colon alleviating symptoms. These findings suggest be used as platform identify nanomedicines various diseases.

Language: Английский

Citations

17
Cracking the intestinal lymphatic system window utilizing oral delivery vehicles for precise therapy DOI Creative Commons
Yang‐Bao Miao,

Tianxing Xu,

Ying Gong

et al.

Journal of Nanobiotechnology, Journal Year: 2023, Volume and Issue: 21(1)

Published: Aug. 10, 2023

Abstract Oral administration is preferred over other drug delivery methods due to its safety, high patient compliance, ease of ingestion without discomfort, and tolerance a wide range medications. However, oral limited by the poor bioavailability many drugs, caused extreme conditions absorption challenges in gastrointestinal tract. This review thoroughly discusses targeted vehicles intestinal lymphatic system (ILS). It explores structure physiological barriers ILS, highlighting significance dietary lipid medication transport. The presents various approaches targeting ILS using spatially precise vehicles, aiming enhance bioavailability, achieve delivery, reduce first-pass metabolism with serve clinic. Furthermore, outlines several for leveraging these open window, paving way potential clinical applications cancer treatment vaccine delivery. By focusing on this article emphasizes critical role strategies improving therapeutic efficacy outcomes. Overall, impact

Language: Английский

Citations

17